Novel Botulinum Toxin Injection Protocols for Parkinson Tremor and Essential Tremor - the Yale Technique and Sensor-Based Kinematics Procedure for Safe and Effective Treatment
- PMID: 33442486
- PMCID: PMC7774361
- DOI: 10.5334/tohm.582
Novel Botulinum Toxin Injection Protocols for Parkinson Tremor and Essential Tremor - the Yale Technique and Sensor-Based Kinematics Procedure for Safe and Effective Treatment
Abstract
Background: Hand tremor associated with Parkinson disease (PD) and essential tremor (ET) can often become challenging to treat in clinical practice. Local injections of botulinum toxin-A (BoNT-A) for hand tremor is an evolving field with newer injection techniques being utilized in clinical studies. The utility of BoNT-A therapy for ET and PD-tremor however, has been questioned based on the high incidence of finger and hand weakness after treatment.
Method: The study includes detailed analysis of the techniques utilized in BoNT injection in ET and PD tremor.
Results: There were 4 high-quality investigations which consisted of Class I or II double-blind placebo-controlled trials and one medium-quality study that was a prospective, open label, class III investigation.
Discussion: This paper discusses two recently developed technology-based injection methods for BoNT-A therapy of ET and PD tremor, which includes comprehensive EMG screening of forearm and arm muscles with selective injections (Yale method) and the whole arm kinematic tremor assessment developed by Jog et al. In recent years, controlled, blinded studies of these two methods have shown significant post-injection reduction of finger, hand and whole limb tremor compared to the previously published controlled clinical trials not using these methodologies.
Keywords: Botulinum neurotoxin; Botulinum toxin; Essential tremor; Parkinson disease tremor; Tremor; incobotulinumtoxinA; onabotulinumtoxinA.
Copyright: © 2020 The Author(s).
Conflict of interest statement
No funding received for this paper. Mittal has no conflict of interest. Jog is a scientific advisor and receives research financial support from the following companies: AbbVie, Allergan Inc., Boston Scientific, Ipsen, MDDT Inc., Medtronic, Merz Pharma, Novartis, and Teva Pharmaceuticals. Lee is a former researcher at the London Movement Disorders Centre and now is an MDDT Inc. employee. Jog and Lee are both shareholders of MDDT Inc. In addition, Jog and Lee are commercializing the medical devices TremorTek™ and Hinge Diagnostics™ and have patents PCT/CA2013/000804, PCT/CA2014/050893 assigned to MDDT Inc. Jabbari has received research financial support in the past from Allergan Inc, Merz Pharma and Ipsen.
Figures
Similar articles
-
Developing a Consistent, Reproducible Botulinum Toxin Type A Dosing Method for Upper Limb Tremor by Kinematic Analysis.Toxins (Basel). 2021 Apr 8;13(4):264. doi: 10.3390/toxins13040264. Toxins (Basel). 2021. PMID: 33917695 Free PMC article.
-
Long-term tremor therapy for Parkinson and essential tremor with sensor-guided botulinum toxin type A injections.PLoS One. 2017 Jun 6;12(6):e0178670. doi: 10.1371/journal.pone.0178670. eCollection 2017. PLoS One. 2017. PMID: 28586370 Free PMC article. Clinical Trial.
-
Transitioning from Unilateral to Bilateral Upper Limb Tremor Therapy for Parkinson's Disease and Essential Tremor Using Botulinum Toxin: Case Series.Toxins (Basel). 2018 Sep 27;10(10):394. doi: 10.3390/toxins10100394. Toxins (Basel). 2018. PMID: 30262746 Free PMC article. Clinical Trial.
-
Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence.J Neural Transm (Vienna). 2009 Mar;116(3):319-31. doi: 10.1007/s00702-008-0175-8. Epub 2009 Jan 14. J Neural Transm (Vienna). 2009. PMID: 19142573 Review.
-
Botulinum toxin type A for hand tremor: a meta-analysis of randomised controlled trials.Neurol Neurochir Pol. 2020;54(6):561-567. doi: 10.5603/PJNNS.a2020.0079. Epub 2020 Oct 13. Neurol Neurochir Pol. 2020. PMID: 33047784
Cited by
-
Clinical assessment of upper limb impairments and functional capacity in Parkinson's disease: a systematic review.Arq Neuropsiquiatr. 2023 Nov;81(11):1008-1015. doi: 10.1055/s-0043-1772769. Epub 2023 Oct 29. Arq Neuropsiquiatr. 2023. PMID: 37899049 Free PMC article.
-
Developing a Consistent, Reproducible Botulinum Toxin Type A Dosing Method for Upper Limb Tremor by Kinematic Analysis.Toxins (Basel). 2021 Apr 8;13(4):264. doi: 10.3390/toxins13040264. Toxins (Basel). 2021. PMID: 33917695 Free PMC article.
-
The Pathophysiology and Treatment of Essential Tremor: The Role of Adenosine and Dopamine Receptors in Animal Models.Biomolecules. 2021 Dec 2;11(12):1813. doi: 10.3390/biom11121813. Biomolecules. 2021. PMID: 34944457 Free PMC article. Review.
-
Real-World Longitudinal Experience of Botulinum Toxin Therapy for Parkinson and Essential Tremor.Toxins (Basel). 2022 Aug 17;14(8):557. doi: 10.3390/toxins14080557. Toxins (Basel). 2022. PMID: 36006219 Free PMC article.
-
Botulinum Toxin Treatment of Motor Disorders in Parkinson Disease-A Systematic Review.Toxins (Basel). 2023 Jan 17;15(2):81. doi: 10.3390/toxins15020081. Toxins (Basel). 2023. PMID: 36828396 Free PMC article.
References
-
- Bhatia KP, Bain P, Bajaj N, Elble RJ, Hallett M, Louis ED, et al. Consensus Statement on the classification of tremors, from the task force on tremor of the International Parkinson and Movement Disorder Society. Movement Disorders. 2018. January; 33(1): 75–87. DOI: 10.1002/mds.27121 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical